新型抗寄生虫化合物BCH070可杀灭环状期恶性疟原虫并保留抗青蒿素耐药活性
研究鉴定出化合物BCH070,对多种抗疟药耐药的恶性疟原虫无性体生长抑制的IC50为1-2 µM,提示其作用机制新颖。BCH070优先杀灭早期环状体滋养体,对携带PfKelch13:C580Y突变的青蒿素耐药株与野生株的环状体存活抑制效果相同。代谢组学分析提示BCH070可能靶向疟原虫多条通路,是开发抗青蒿素耐药新型联合疗法的有前景的先导化合物。
要点
- BCH070对多种抗疟药耐药恶性疟原虫株的IC50为1-2 µM
- BCH070优先杀灭早期环状体,对PfKelch13:C580Y耐药株环状体存活抑制与野生株相同
- 代谢组学提示BCH070可能靶向多条通路,机制新颖
核心结论
- BCH070是有前景的先导化合物,可用于开发对青蒿素耐药疟原虫仍保留活性的新型抗疟联合疗法。
研究设计与样本
- 体外研究:检测化合物BCH070对多种抗疟药耐药恶性疟原虫株无性体生长的抑制作用,并进行代谢组学分析。
主要发现
- BCH070抑制多种抗疟药耐药恶性疟原虫株无性体生长,IC50=1-2 µM,提示作用机制新颖。
- BCH070优先杀灭早期环状体滋养体,对携带PfKelch13:C580Y突变的青蒿素耐药株与野生型环状体存活抑制效果相同。
- 代谢组学分析提示BCH070可能靶向疟原虫多条通路。
关键数值与推荐
- BCH070对多种抗疟药耐药恶性疟原虫株的IC50=1-2 µM。
- 青蒿素耐药株携带PfKelch13:C580Y突变,其环状体存活受BCH070抑制程度与野生型相同。
临床怎么用
- BCH070尚处先导化合物阶段,可作为研发抗青蒿素耐药疟原虫新型联合疗法的候选分子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spreading antimalarial resistance threatens effective treatment of malaria, an infectious disease caused by Plasmodium parasites. We identified a compound, BCH070, that inhibits asexual growth of multiple antimalarial-resistant strains of Plasmodium falciparum (half maximal inhibitory concentration [IC50] = 1-2 µM), suggesting that BCH070 acts via a novel mechanism of action. BCH070 preferentially kills early ring-form trophozoites, and, importantly, equally inhibits ring-stage survival of wild-type and artemisinin-resistant parasites harboring the PfKelch13:C580Y mutation. Metabolomic analysis demonstrates that BCH070 likely targets multiple pathways in the parasite. BCH070 is a promising lead compound for development of new antimalarial combination therapy that retains activity against artemisinin-resistant parasites.
引用
- Clements RL, Streva V, Dumoulin P, et al. A Novel Antiparasitic Compound Kills Ring-Stage Plasmodium falciparum and Retains Activity Against Artemisinin-Resistant Parasites. J Infect Dis. 2020. PMID: 31616928. doi:10.1093/infdis/jiz534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。